Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

Phospho-proteomic analysis of mantle cell lymphoma cells suggests a pro-survival role of B-cell receptor signaling
Chiara Pighi, Ting‐Lei Gu, Irene Dalai, et al.
Cellular Oncology (2011) Vol. 34, Iss. 2, pp. 141-153
Open Access | Times Cited: 76

Showing 1-25 of 76 citing articles:

Role of Bruton’s tyrosine kinase in B cells and malignancies
Simar Pal Singh, Floris Dammeijer, Rudi W. Hendriks
Molecular Cancer (2018) Vol. 17, Iss. 1
Open Access | Times Cited: 606
Targeting Bruton's tyrosine kinase in B cell malignancies
Rudi W. Hendriks, Saravanan Yuvaraj, Laurens P. Kil
Nature reviews. Cancer (2014) Vol. 14, Iss. 4, pp. 219-232
Open Access | Times Cited: 486
Biological activity of piceatannol: Leaving the shadow of resveratrol
H. Piotrowska, Małgorzata Kucińska, Marek Murias
Mutation Research/Reviews in Mutation Research (2011) Vol. 750, Iss. 1, pp. 60-82
Closed Access | Times Cited: 434
Molecular pathogenesis of mantle cell lymphoma
Pedro Jares, Dolors Colomer, Elı́as Campo
Journal of Clinical Investigation (2012) Vol. 122, Iss. 10, pp. 3416-3423
Open Access | Times Cited: 359
Mass Spectrometry-Based Detection and Assignment of Protein Posttranslational Modifications
Sophia Doll, Alma L. Burlingame
ACS Chemical Biology (2014) Vol. 10, Iss. 1, pp. 63-71
Open Access | Times Cited: 225
Inhibition of Btk with CC-292 Provides Early Pharmacodynamic Assessment of Activity in Mice and Humans
Erica Evans, Richland Tester, Sharon Aslanian, et al.
Journal of Pharmacology and Experimental Therapeutics (2013) Vol. 346, Iss. 2, pp. 219-228
Closed Access | Times Cited: 216
BTK inhibitors in the treatment of hematological malignancies and inflammatory diseases: mechanisms and clinical studies
Aqu Alu, Hong Lei, Xuejiao Han, et al.
Journal of Hematology & Oncology (2022) Vol. 15, Iss. 1
Open Access | Times Cited: 90
Bruton Tyrosine Kinase (BTK) and Its Role in B-cell Malignancy
Joseph J. Buggy, Laurence Elias
International Reviews of Immunology (2012) Vol. 31, Iss. 2, pp. 119-132
Closed Access | Times Cited: 205
Egress of CD19+CD5+ cells into peripheral blood following treatment with the Bruton tyrosine kinase inhibitor ibrutinib in mantle cell lymphoma patients
Betty Chang, Michelle Francesco, Martin F. M. de Rooij, et al.
Blood (2013) Vol. 122, Iss. 14, pp. 2412-2424
Open Access | Times Cited: 197
Resistance to Bruton tyrosine kinase inhibition in chronic lymphocytic leukaemia and non‐Hodgkin lymphoma
Shazia Nakhoda, Aldana Vistarop, Y. Lynn Wang
British Journal of Haematology (2022) Vol. 200, Iss. 2, pp. 137-149
Open Access | Times Cited: 64
From development to clinical success: the journey of established and next-generation BTK inhibitors
Shivani Gupta, Arpit Sharma, Alok Kumar Shukla, et al.
Investigational New Drugs (2025)
Closed Access | Times Cited: 1
Selective inhibitors of phosphoinositide 3-kinase delta: modulators of B-cell function with potential for treating autoimmune inflammatory diseases and B-cell malignancies
Kamal D. Puri, Michael R. Gold
Frontiers in Immunology (2012) Vol. 3
Open Access | Times Cited: 98
Regulation of cardiac proteasomes by ubiquitination, SUMOylation, and beyond
Ziyou Cui, Sarah B. Scruggs, Jennifer E. Gilda, et al.
Journal of Molecular and Cellular Cardiology (2013) Vol. 71, pp. 32-42
Open Access | Times Cited: 84
Characterization of ibrutinib‐sensitive and ‐resistant mantle lymphoma cells
Jiao Ma, Pin Lu, Ailin Guo, et al.
British Journal of Haematology (2014) Vol. 166, Iss. 6, pp. 849-861
Closed Access | Times Cited: 83
Phosphorylation of β-arrestin2 at Thr383 by MEK underlies β-arrestin-dependent activation of Erk1/2 by GPCRs
Elisabeth Cassier, Nathalie Gallay, Thomas Bourquard, et al.
eLife (2017) Vol. 6
Open Access | Times Cited: 67
Mechanisms of B Cell Receptor Activation and Responses to B Cell Receptor Inhibitors in B Cell Malignancies
Dimitar G. Efremov, Sven Turkalj, Luca Laurenti
Cancers (2020) Vol. 12, Iss. 6, pp. 1396-1396
Open Access | Times Cited: 67
Regulation of histone deacetylase activities and functions by phosphorylation and its physiological relevance
Sonali Bahl, Edward Seto
Cellular and Molecular Life Sciences (2020) Vol. 78, Iss. 2, pp. 427-445
Open Access | Times Cited: 51
Flavor formation by amino acid catabolism in low-salt sufu paste, a Chinese fermented soybean food
Chunzhi Xie, Likang Qin, Na Liu, et al.
Food Bioscience (2024) Vol. 59, pp. 104228-104228
Closed Access | Times Cited: 8
B-Cell Receptor Signaling Inhibitors for Treatment of Autoimmune Inflammatory Diseases and B-Cell Malignancies
Kamal D. Puri, Julie A. Di Paolo, Michael R. Gold
International Reviews of Immunology (2013) Vol. 32, Iss. 4, pp. 397-427
Closed Access | Times Cited: 65
Microenvironment dependency in Chronic Lymphocytic Leukemia: The basis for new targeted therapies
Elisa ten Hacken, Jan A. Burger
Pharmacology & Therapeutics (2014) Vol. 144, Iss. 3, pp. 338-348
Closed Access | Times Cited: 57
Activation of MYC, a bona fide client of HSP90, contributes to intrinsic ibrutinib resistance in mantle cell lymphoma
Jimmy Lee, Liang Leo Zhang, Wenjun Wu, et al.
Blood Advances (2018) Vol. 2, Iss. 16, pp. 2039-2051
Open Access | Times Cited: 55
IRAK-4 inhibition: emavusertib for the treatment of lymphoid and myeloid malignancies
Ricardo Parrondo, Madiha Iqbal, Reinhard von Roemeling, et al.
Frontiers in Immunology (2023) Vol. 14
Open Access | Times Cited: 14
The microenvironment in mantle cell lymphoma: Cellular and molecular pathways and emerging targeted therapies
Jan A. Burger, R. Ford
Seminars in Cancer Biology (2011) Vol. 21, Iss. 5, pp. 308-312
Closed Access | Times Cited: 57
Inhibiting B-Cell Receptor Signaling Pathways in Chronic Lymphocytic Leukemia
Jan A. Burger
Current Hematologic Malignancy Reports (2011) Vol. 7, Iss. 1, pp. 26-33
Closed Access | Times Cited: 53
Inhibitors of BCR signalling interrupt the survival signal mediated by the micro‐environment in mantle cell lymphoma
Sophie Bernard, Damien Danglade, Laura Gardano, et al.
International Journal of Cancer (2014) Vol. 136, Iss. 12, pp. 2761-2774
Open Access | Times Cited: 50
Page 1 - Next Page

Scroll to top